Chemo may be preferred option for some with advanced prostate cancer
the ONA take:
According to the results of a small clinical trial published online in JAMA Oncology, researchers from Johns Hopkins' Kimmel Cancer Center and James Buchanan Brady Urological Institute in Baltimore, Maryland, have found that men with advanced prostate cancer who possess the androgen receptor splice variant-7 (AR-V7) respond just as well to chemotherapy as those who lack AR-V7.
The AR-V7 gene variant has been shown to confer resistance to enzalutamide or abiraterone, two hormonal drugs used to treated castration-resistant prostate cancer; however, the study found that patients with the variant respond similarly to docetaxel or cabazitaxel compared with those without the gene variant.
"Our study shows that men who have the AR-V7 gene variant and usually don't respond to either abiraterone or enzalutamide, are not at a disadvantage when given chemotherapy drugs," says Emmanuel Antonarakis, M.D., an oncologist at the Kimmel Cancer Center.
The researchers are currently working to develop and validate a test to detect AR-V7 in patients with advanced prostate cancer to better inform treatment decisions.
Men with advanced prostate cancer who possess AR-V7 respond just as well to chemotherapy as those who lack AR-V7.
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Adding Bevacizumab to Adjuvant Capecitabine Not Effective for mCRC
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Definitive IMRT Associated With Shorter Feeding Tube Placement Duration in HNC
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|